Tobramycin (TOBI？？？？ or TOBI PODHALER？？？？) in Ventilator Associated Pneumonia: An Overview | Insight Medical Publishing

Despite the fact that Ventilator Associated Pneumonia (VAP) has a high death rate, it is not yet defined very well. Mortality in patients with lung injury on mechanical ventilation is estimated as 24% in patients 15-19 years and 60% in patients 85 years or older. Very few studies have reported the use of tobramycin (TOBI？ or Tobi Podhaler？) in VAP management. However, the use of such antibiotics for treatment of VAP is equivocal and no clinical evidences reported. Tobi Podhaler？ contains active substance of tobramycin, which is available as capsules (28 mg). Tobi Podhaler？ can be used as a hand-held device which suppresses the chronic lung infections caused by P. aeruginosa in patients aged >6 years. The recommended dose is four capsules twice a day in adults and children older than 6 years of age. It can be also used to treat Cystic Fibrosis (CF). This review highlights the advantages of treatment with TOBI (Tobi Podhaler？) in VAP patients and also a note on inhaled antibiotics in management of chronic respiratory infections.